Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Natco Pharma to focus...

    Natco Pharma to focus to scale up Cancer treatment biz in China: MD VC Nannapaneni

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-12T12:26:57+05:30  |  Updated On 17 Aug 2021 10:40 AM IST

    New Delhi: Natco Pharma is focusing on filing of cancer treatment drugs in China, the world's second largest pharmaceutical market, as part of its strategy to diversify business in various emerging markets amid headwinds in the US.


    Addressing shareholders in the company's Annual Report for 2018-19, Natco Pharma Chairman and Managing Director V C Nannapaneni said the company had foreseen imminent headwinds in the US market and had began diversifying its resources towards building businesses in new markets. Those investments are now reaping rewards, he added.


    "We are currently investing to further establish our presence in Australia, Singapore, China and South East Asian countries and are confident that our businesses in these markets will propel growth in the future," Nannapaneni said.


    In the near term, growth for the company would continue to be driven by markets like India, Brazil and Canada, he added.


    "As we continually balance our portfolio of products and growth in the US, we expect majority of revenue to be coming from non-US markets," Nannapaneni said.


    Commenting on the company's plans in the China market, he added that it is focusing on filing of oncology products in the country.


    China is the second largest pharmaceutical market globally with total spending of USD 137 billion in 2018. Government reforms to improve insurance access and recent upgrades in the hospital and primary care infrastructure have led to increase in spending on healthcare initiatives.


    Read Also: Natco Pharma gets zero USFDA observations for Chennai facility


    China's pharma market is likely to grow at 3-6 per cent to USD 140-170 billion by 2023 as against Brazil which is likely to grow at 5-8 per cent to USD 30-43 billion.


    Nannapaneni also said the drug firm has also begun exploratory work for expansion into Africa.


    "We believe that this will help us diversify further into new geographies for growth," he said.


    Read Also: Natco Pharma gets EIR from USFDA for Kothur facility

    cancerCEOchina pharma marketHealthcareMDNatcoNatco pharmapharmapharma companypharma companyNatco Pharmapharma newsV C NannapaneniVC Nannapaneni
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok